A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens

Vaccine

Volumn 31, Issue 36, 2013, Pages 3732-3738

  Berbers, G A M ^a   van de Wetering, M S E ^a   van Gageldonk, P G M ^a   Schellekens, J F P ^c   Versteegh, F G A ^d   Teunis, P F M ^a,b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b EMORY UNIVERSITY   (United States)

^c Laboratorium Voor Infectieziekten   (Netherlands)

^d GROENE HART HOSPITAL   (Netherlands)

Author keywords

Acellular; Infection; Mixed model; Pertussis; Serology; Vaccine; Whole cell

Indexed keywords

HEMAGGLUTININ; PERTUSSIS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; FOLLOW UP; LIMIT OF QUANTITATION; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; VACCINE PRODUCTION;

ACELLULAR; INFECTION; MIXED MODEL; PERTUSSIS; SEROLOGY; VACCINE; WHOLE CELL;

ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BACTERIAL OUTER MEMBRANE PROTEINS; CHILD; CHILD, PRESCHOOL; HEMAGGLUTININS; HUMANS; IMMUNOGLOBULIN G; INFANT; LONGITUDINAL STUDIES; NONLINEAR DYNAMICS; PERTUSSIS TOXIN; PERTUSSIS VACCINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, ACELLULAR; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 84880944071     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.073     Document Type: Article

References (41)

1. Wirsing von Konig C.H., Halperin S., Riffelmann M., Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002, 2(December (12)):744-750.
2. de Melker H.E., Schellekens J.F., Neppelenbroek S.E., Mooi F.R., Rumke H.C., Conyn-van Spaendonck M.A. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis 2000, 6(July-August (4)):348-357.
3. de Greeff S.C., de Melker H.E., van Gageldonk P.G., Schellekens J.F., van der Klis F.R., Mollema L., et al. Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS ONE 2010, 5(12):e14183.
4. Mooi F.R., van Loo I.H., King A.J. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence. Emerg Infect Dis 2001, 7(3 Suppl.):526-528.
5. He Q., Mertsola J. Factors contributing to pertussis resurgence. Future Microbiol 2008, 3(June (3)):329-339.
6. van Boven M., Mooi F.R., Schellekens J.F., de Melker H.E., Kretzschmar M. Pathogen adaptation under imperfect vaccination: implications for pertussis. Proc Biol Sci 2005, 272(August (1572)):1617-1624.
7. Crowcroft N.S., Pebody R.G. Recent developments in pertussis. Lancet 2006, 367(June (9526)):1926-1936.
8. Klein N.P., Bartlett J., Rowhani-Rahbar A., Fireman B., Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012, 367(September (11)):1012-1019.
9. Berbers G.A., de Greeff S.C., Mooi F.R. Improving pertussis vaccination. Hum Vaccines 2009, 5(July (7)):497-503.
10. Cherry J.D. Why do pertussis vaccines fail?. Pediatrics 2012, 129(May (5)):968-970.
11. Giammanco A., Taormina S., Genovese M., Mangiaracina G., Giammanco G., Chiarini A. Serological responses to infection with B. pertussis. Dev Biol Stand 1997, 89:213-220.
12. Hodder S.L., Cherry J.D., Mortimer E.A., Ford A.B., Gornbein J., Papp K. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis 2000, 31(July (1)):7-14.
13. Saemann-Ischenko G., Tillmanns B., Kosters K., Riffelmann M., Wirsing von Konig C.H. Stability of antibodies to Bordetella antigens in German adults. Eur J Clin Microbiol Infect Dis 2001, 20(December (12)):850-853.
14. Heininger U., Cherry J.D., Stehr K. Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis 2004, 38(February (4)):591-594.
15. Isacson J., Trollfors B., Hedvall G., Taranger J., Zackrisson G. Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis. Scand J Infect Dis 1995, 27(3):273-277.
16. Giuliano M., Mastrantonio P., Giammanco A., Bottone M., Piscitelli A., Di Tommaso S., et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Dev Biol Stand 1997, 89:275-278.
17. Giuliano M., Mastrantonio P., Giammanco A., Piscitelli A., Salmaso S., Wassilak S.G. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatr 1998, 132(June (6)):983-988.
18. Grimprel E., Begue P., Anjak I., Njamkepo E., Francois P., Guiso N. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin Diagn Lab Immunol 1996, 3(January (1)):93-97.
19. Teunis P.F., van der Heijden O.G., de Melker H.E., Schellekens J.F., Versteegh F.G., Kretzschmar M.E. Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis. Epidemiol Infect 2002, 129(December (3)):479-489.
20. Hallander H.O., Gustafsson L., Ljungman M., Storsaeter J. Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine 2005, 23(November (46-47)):5359-5364.
21. Versteegh F.G., Mertens P.L., de Melker H.E., Roord J.J., Schellekens J.F., Teunis P.F. Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis. Epidemiol Infect 2005, 133(August (4)):737-748.
22. Markov Chain Monte Carlo in practice 1996, Chapman and Hall, London. W.R.R.S. Gilks, D.J. Spiegelhalter (Eds.).
23. Berbers G.A.M., Lafeber A.B., Labadie J., Vermeer-de Bondt P.E., Bolscher D.J.A., Plantinga A.D. A randomised controlled study with whole-cell or acellular pertussis vaccines in combination with regular DT-IPV vaccine and a new poliomyelitis (IPV vero) component in children 4 years of age in the Netherlands. RIVM Report 105000001, Bilthoven 1999, Report No.: RIVM Rapport 105000001.
24. Edwards K.M., Meade B.D., Decker M.D., Reed G.F., Rennels M.B., Steinhoff M.C., et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995, 96(September (3 Pt 2)):548-557.
25. Meade B.D., Deforest A., Edwards K.M., Romani T.A., Lynn F., O'Brien C.H., et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 1995, 96(September (3 Pt 2)):570-575.
26. van Gageldonk P.G.M., van Schaijk F.G., van der Klis F.R.M., Berbers G.A.M. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods 2008, 335(June (1-2)):79-89.
27. Simonsen J., Molbak K., Falkenhorst G., Krogfelt K.A., Linneberg A., Teunis P.F. Estimation of incidences of infectious diseases based on antibody measurements. Stat Med 2009, 28(June (14)):1882-1895.
28. Teunis P.F., van Eijkeren J.C., Ang C.W., van Duynhoven Y.T., Simonsen J.B., Strid M.A., et al. Biomarker dynamics: estimating infection rates from serological data. Stat Med 2012, 31(September (20)):2240-2248.
29. Teunis P.F., Schimmer B., Notermans D.W., Leenders A.C., Wever P.C., Kretzschmar M.E., et al. Time-course of antibody responses against Coxiella burnetii following acute Q fever. Epidemiol Infect 2013, 141(January (1)):62-73.
30. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357(November (19)):1903-1915.
31. Dalby T., Petersen J.W., Harboe Z.B., Krogfelt K.A. Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine. J Med Microbiol 2010, 59(September (Pt 9)):1029-1036.
32. Hallander H.O., Ljungman M., Storsaeter J., Gustafsson L. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. APMIS 2009, 117(November (11)):797-807.
33. Mertsola J., Van Der Meeren O., He Q., Linko-Parvinen A., Ramakrishnan G., Mannermaa L., et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis 2010, 51(September (6)):656-662.
34. Fraser C., Tomassini J.E., Xi L., Golm G., Watson M., Giuliano A.R., et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 2007, 25(May (21)):4324-4333.
35. Bailleux F., Coudeville L., Kolenc-Saban A., Bevilacqua J., Barreto L., Andre P. Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine 2008, 26(July (31)):3903-3908.
36. Le T., Cherry J.D., Chang S.J., Knoll M.D., Lee M.L., Barenkamp S., et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis 2004, 190(August (3)):535-544.
37. Edelman K., He Q., Makinen J., Sahlberg A., Haanpera M., Schuerman L., et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis 2007, 44(May (10)):1271-1277.
38. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998, 16(December (20)):1907-1916.
39. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998, 16(December (20)):1901-1906.
40. Taranger J., Trollfors B., Lagergard T., Sundh V., Bryla D.A., Schneerson R., et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 2000, 181(March (3)):1010-1013.
41. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 2003, 21(September (25-26)):3542-3549.